News & Updates

Show Multimedia Only

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

30 Nov 2021

Hepatic venous pressure gradient (HVPG)-guided prophylaxis with non-selective beta blockers (NSBB) seems to be reasonably effective in patients with nonalcoholic steatohepatitis (NASH), eliciting responses from around half of this population, a recent study has found.

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

30 Nov 2021

Phase II data underscores lanifibranor potential for NASH

30 Nov 2021 by

In the phase IIb NATIVE* trial, the pan-PPAR** agonist lanifibranor demonstrated histologic benefits for patients with nonalcoholic steatohepatitis (NASH).

Phase II data underscores lanifibranor potential for NASH

30 Nov 2021

Statins not only good for the heart, but also the liver

27 Nov 2021 by

Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.

Statins not only good for the heart, but also the liver

27 Nov 2021

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

27 Nov 2021

Plasma levels of PRO-C3, a serological biomarker for the detection of the formation of type III collagen, can act as a good indicator of disease activity and fibrosis in nonalcoholic fatty liver disease (NAFLD), a recent study has found.

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

27 Nov 2021

Bariatric surgery may be the go-to strategy for NASH in the obese

25 Nov 2021 by

Bariatric surgery significantly lowers the risk of major adverse liver outcomes and major adverse cardiovascular events (MACE) – the dual primary endpoints – in obese patients with biopsy-driven nonalcoholic steatohepatitis (NASH) in the SPLENDOR* study.

Bariatric surgery may be the go-to strategy for NASH in the obese

25 Nov 2021

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden

22 Nov 2021 by

Aspirin safely lowers the risk of hepatocellular carcinoma (HCC) among chronic hepatitis B (CHB) patients suffering from a heavy burden of metabolic risk, according to a study presented at The Liver Meeting Digital Experience 2021 of the American Association for the Study of Liver Diseases (AASLD 2021).

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden

22 Nov 2021

Metabolic dysfunction-associated fatty liver disease may harm pregnancy

22 Nov 2021

Metabolic dysfunction-associated fatty liver disease contributes to an increased risk of subsequent unfavourable pregnancy outcomes, a study reports.

Metabolic dysfunction-associated fatty liver disease may harm pregnancy

22 Nov 2021

In the waiting line for liver transplants: Women remain disadvantaged

20 Nov 2021 by

Access to liver transplantation suffers from a persistent and unacceptable gender gap, with female candidates on the wait list being much less likely to receive a transplant and facing a higher risk of dying than their male counterparts, according to an expert.

In the waiting line for liver transplants: Women remain disadvantaged

20 Nov 2021

Protease-based liquid biopsy a promising approach for diagnosing fatty liver disease

19 Nov 2021 by

A liquid biopsy platform that utilizes protease biosensors can detect nonalcoholic steatohepatitis with pinpoint accuracy in both mice and humans.

Protease-based liquid biopsy a promising approach for diagnosing fatty liver disease

19 Nov 2021

COVID-19 vaccines weaker in liver transplant recipients, CLD patients

19 Nov 2021 by

Vaccines against the coronavirus disease 2019 (COVID-19) induce weaker and more transient immune responses in liver transplant recipients, those with cirrhosis, or those with chronic liver disease (CLD), according to a study presented at The Liver Meeting Digital Experience 2021 by the American Association for the Study of Liver Diseases (AASLD 2021).

COVID-19 vaccines weaker in liver transplant recipients, CLD patients

19 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

More than half of NASH patients respond to HVPG-guided NSBB prophylaxis

Phase II data underscores lanifibranor potential for NASH

Phase II data underscores lanifibranor potential for NASH

Statins not only good for the heart, but also the liver

Statins not only good for the heart, but also the liver

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

PRO-C3 levels, ADAPT score accurately detect fibrosis in NAFLD

Bariatric surgery may be the go-to strategy for NASH in the obese

Bariatric surgery may be the go-to strategy for NASH in the obese

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden

Aspirin cuts HCC risk in CHB patients with heavy metabolic burden

Metabolic dysfunction-associated fatty liver disease may harm pregnancy

Metabolic dysfunction-associated fatty liver disease may harm pregnancy

In the waiting line for liver transplants: Women remain disadvantaged

In the waiting line for liver transplants: Women remain disadvantaged

Protease-based liquid biopsy a promising approach for diagnosing fatty liver disease

Protease-based liquid biopsy a promising approach for diagnosing fatty liver disease

COVID-19 vaccines weaker in liver transplant recipients, CLD patients

COVID-19 vaccines weaker in liver transplant recipients, CLD patients